---
title: "Lysergide (DT120) in Generalized anxiety disorder: Pathophysiology"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Pathophysiology. Topics: Threat-response circuitry: anxiety disorders, Amygdala subregion connectivity and a compensatory frontoparietal network: resting-state fMRI, Amygdala-prefrontal connectivity and physiological arousal, Task-based affective neuroimaging: variable limbic and prefrontal findings, and 8 further topics. 12 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Threat-response circuitry: anxiety disorders

> “This research suggests that perturbed threat responding in anxiety disorders involves dysfunction in the circuitry that supports core psychological processes, such as attention, emotion, learning, and memory.”
> “Many brain imaging studies have examined the structure of regions that basic neuroscience implicates in threat responding, showing structural alterations in anxiety disorders within medial temporal, prefrontal cortex, and cingulate regions.”
> “With functional MRI, patients who are anxious have an altered response in temporal and prefrontal brain regions, which has also been shown in functional MRI research regarding attention.”
> “When people are exposed to stressors, such as public speaking, scary pictures, or painful stimulation, studies generally report increased stress responses in people with anxiety disorders versus controls across many measures.”
> “For peripheral measures, rarely do effect sizes exceed a Cohen’s d of 0·50, indicating that these are not useful biomarkers that currently guide diagnosis.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.4-2"></a>

### Amygdala subregion connectivity and a compensatory frontoparietal network: resting-state fMRI

> “In GAD patients, BLA and CMA connectivity patterns were significantly less distinct, and increased gray matter volume was noted primarily in the CMA. Across the subregions, GAD patients had increased connectivity with a previously characterized frontoparietal executive control network and decreased connectivity with an insula- and cingulate-based salience network.”
> “In GAD, we find evidence of an intra-amygdalar abnormality and engagement of a compensatory frontoparietal executive control network, consistent with cognitive theories of GAD.”

Source: [Etkin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12553334/)

<a id="topic-2.2.1.4-3"></a>

### Amygdala-prefrontal connectivity and physiological arousal

> “The disrupted coordination of brain activity has been proposed as one of the core neurobiological features of GAD,”
> “Findings suggest that across adolescence and adulthood, decreased connectivity between the amygdala and PFC is associated with the diagnosis of GAD.”
> “In general, the psychophysiological literature demonstrates that individuals with GAD are in a more physiologically dysregulated state (e.g., low HRV, high heart rate, higher skin conductance levels) at baseline relative to controls”
> “Yet, this hyperarousal psychophysiological pattern in GAD is not universally observed.”

Source: [Patriquin and Mathew (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/)

<a id="topic-2.2.1.4-4"></a>

### Task-based affective neuroimaging: variable limbic and prefrontal findings

> “Studies provide evidence for variable presence and directionality of BOLD abnormalities in limbic and prefrontal regions during reactivity to, regulation of, and learning from emotional cues.”
> “We propose that the cardinal symptom of GAD—worry—predominantly reflects stimulus-independent mental processes that impose abnormal, inflexible functional brain configurations, ie, the overall pattern of information transfer among behaviorally relevant neural circuits at a given point in time.”

Source: [Fonzo and Etkin (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573561/)

<a id="topic-2.2.1.4-5"></a>

### Brain structure: ENIGMA-Anxiety mega-analysis, 28 sites

> “The main analysis (1020 individuals with GAD and 2999 healthy controls) included random slopes per site and random intercepts per scanner.”
> “The main analysis showed no effect of GAD on brain structure, nor interactions involving GAD, age, or sex.”

Source: [Harrewijn et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8486763/)

<a id="topic-2.2.1.4-6"></a>

### Emotional hyperreactivity and worry: Contrast Avoidance model

> “A synthesis of these data points to a central role of emotional hyperreactivity, sensitivity to contrasting emotions, and dysfunctional attempts to cope with strong emotional shifts via worry. Consistent with the Contrast Avoidance model, evidence shows that worry evokes and sustains negative affect, thereby precluding sharp increases in negative emotion.”
> “Consistent with this vulnerability, functional magnetic resonance imaging studies of GAD cumulatively suggest hyperresponsivity of the amygdala, the limbic structure that mediates negatively valenced affective reactions, and fear in particular (Schienle et al. 2011).”

Source: [Newman et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4964851/)

<a id="topic-2.2.1.4-7"></a>

### Neurotransmitter systems: serotonergic and noradrenergic activity

> “The exact mechanism underlying generalized anxiety disorder remains unclear.”
> “Noradrenergic, serotonergic, and other neurotransmitter systems appear to play a role in the body's response to stress. The serotonin and noradrenergic systems are common pathways involved in anxiety. Reduced serotonergic activity and increased noradrenergic activity may contribute to the development of generalized anxiety disorder.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.4-8"></a>

### Serotonin receptor subtypes: 5-HT1A and 5-HT2A signaling in anxiety

> “Like impulsivity and aggression, anxiety appears to be negatively modulated by 5-HT1AR stimulation”
> “The serotonin 2A receptor has also been implicated in anxiety. Serotonin 2A receptor knock-out mice display reduced anxiety which is normalised when its functioning is recovered (Weisstaub et al., 2006). These findings suggest that 5-HT2AR signalling has an anxiogenic effect that is opposite to the anxiolytic effect of postsynaptic 5-HT1AR activation.”
> “Thus, whereas postsynaptic 5-HT1AR activation appears to moderate anxiety and stress, the effect of 5-HT2AR activation is more complex (Carhart-Harris et al., 2016c).”

Source: [Carhart-Harris and Nutt (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5606297/)

<a id="topic-2.2.1.4-9"></a>

### Serotonin 2A receptor binding and trait anxiety: PET in healthy volunteers

> “Neuroticism correlated positively with frontolimbic serotonin 2A receptor binding [r(79) = .24, p = .028]. Post hoc analysis of the contributions from the six constituent traits of neuroticism showed that the correlation was primarily driven by two of them: vulnerability and anxiety.”

Source: [Frokjaer et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17884017/)

<a id="topic-2.2.1.4-10"></a>

### GABAergic signaling: genetic risk for major anxiety disorders

> “Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism implicated in ANX genetic risk.”

Source: [Strom et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12900644/)

<a id="topic-2.2.1.4-11"></a>

### Inflammation: peripheral inflammatory markers

> “CRP was significantly higher in people with GAD compared with controls, with a small effect size (Cohen’s d=0.38, 0.06–0.69), comparable with that reported in schizophrenia.”
> “There is preliminary evidence to suggest an inflammatory response in GAD, but it remains unclear whether inflammatory cytokines play a role in the aetiology.”

Source: [Costello et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6661660/)

<a id="topic-2.2.1.4-12"></a>

### Sponsor statement on brain circuitry in generalized anxiety disorder

> “GAD involves disrupted activity, connectivity, or neuroplasticity in key regions of the brain such as the prefrontal cortex, amygdala, and thalamus, leading to impaired emotional regulation and clinical symptoms.”

Source: [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf)

> “Wired for Worry is designed to meet a critical need to broaden understanding of GAD through evidence-based education, including how it may result from dysregulated brain circuitry that contributes to chronic symptoms and functional impairment.”

Source: [Definium Therapeutics Wired for Worry announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/238/definium-therapeutics-launches-wired-for-worry-a-health-care-provider-initiative-to-advance-the-understanding-of-generalized-anxiety-disorder-gad-patient-impact-and-neurobiology)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
